“We are dropping coverage of Bioverativ , Inc. following the completion of its acquisition by Sanofi (SNY $39.90). Our final rating on Bioverativ was Market Perform.”,” the firm’s analyst wrote.
BIVV has been the topic of a number of other reports. Credit Suisse Group restated a neutral rating on shares of Bioverativ in a research report on Wednesday, January 24th. Argus reaffirmed a hold rating on shares of Bioverativ in a report on Wednesday, January 24th. Zacks Investment Research downgraded Bioverativ from a buy rating to a hold rating in a report on Wednesday, January 3rd. Morgan Stanley raised Bioverativ from an underweight rating to an equal weight rating in a report on Tuesday, January 23rd. Finally, Piper Jaffray Companies downgraded Bioverativ from an overweight rating to a neutral rating in a report on Monday, January 22nd. Thirteen analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. The stock has an average rating of Hold and an average price target of $63.15.
Bioverativ (NASDAQ:BIVV) last announced its earnings results on Tuesday, February 13th. The biotechnology company reported $0.76 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.75 by $0.01. The business had revenue of $328.70 million for the quarter, compared to analyst estimates of $325.89 million. Bioverativ had a net margin of 30.43% and a return on equity of 40.99%. analysts forecast that Bioverativ will post 3.82 EPS for the current fiscal year.
Hedge funds and other institutional investors have recently modified their holdings of the stock. Robeco Institutional Asset Management B.V. acquired a new stake in Bioverativ in the fourth quarter valued at $105,000. American Assets Investment Management LLC acquired a new stake in Bioverativ in the fourth quarter valued at $108,000. Advisors Asset Management Inc. acquired a new stake in Bioverativ in the third quarter valued at $137,000. Ladenburg Thalmann Financial Services Inc. acquired a new stake in Bioverativ in the third quarter valued at $190,000. Finally, Canada Pension Plan Investment Board acquired a new stake in Bioverativ in the third quarter valued at $194,000. 97.18% of the stock is owned by hedge funds and other institutional investors.
WARNING: This piece was reported by Sports Perspectives and is the sole property of of Sports Perspectives. If you are accessing this piece on another publication, it was copied illegally and reposted in violation of US & international copyright legislation. The original version of this piece can be read at https://sportsperspectives.com/2018/03/12/bioverativ-bivv-stock-rating-reaffirmed-by-william-blair.html.
Bioverativ Inc (Bioverativ) is a biotechnology company. The Company is focused on the discovery, research, development and commercialization of therapies for the treatment of hemophilia and other blood disorders. It markets approximately two products, including ELOCTATE [Antihemophilic Factor (Recombinant), Fc Fusion Protein], and ALPROLIX [Coagulation Factor IX (Recombinant), Fc Fusion Protein], extended half-life clotting-factor therapies for the treatment of hemophilia A and hemophilia B, respectively.
Receive News & Ratings for Bioverativ Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bioverativ and related companies with MarketBeat.com's FREE daily email newsletter.